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Background. Dedifferentiated chondrosarcomas (DDCSs) are highly malignant tumors with a dismal prognosis and present a
significant challenge in clinical management.Methods. In an IRB approved retrospective protocol, we identified 72 patients with
DDCS treated at our institution between 1993 and 2017 and reviewed clinicopathological characteristics, treatment modalities,
and outcomes to analyze prognostic factors. Results. Femur (44.4%), pelvis (22.2%), and humerus (12.5%) were most commonly
involved sites. Twenty-three patients (31.9%) presented with distant metastasis, and 3 (4.2%) of them also had regional lymph
node involvement. ,e median overall survival (OS) was 13.9 months. On multivariate analysis, pathological fracture, larger
tumor size, lymph node involvement, metastasis at diagnosis, extraosseous extension, and undifferentiated pleomorphic sarcoma
component correlated with worse OS, whereas surgical resection and chemotherapy were associated with improved OS. For
progression-free survival (PFS), pathological fracture and metastasis at diagnosis showed increased risk, while chemotherapy was
associated with decreased risk. Among patients who received chemotherapy, doxorubicin and cisplatin were significantly as-
sociated with improved PFS but not OS. Among patients without metastasis at diagnosis, 17 (34.7%) developed local recurrence.
,irty-one (63.3%) developed distant metastases at a median interval of 18.1 months. On multivariate analysis, R1/R2 resection
was related with local recurrence, while macroscopic dedifferentiated component was associated with distant metastasis.
Conclusions. ,e prognosis of DDCS is poor. Complete resection remains a significant prognostic factor for local control.
Chemotherapy with doxorubicin and cisplatin seems to have better PFS. More prognostic, multicenter trials are warranted to
further explore the effectiveness of chemotherapy in selected DDCS patients.
1. Introduction
Dedifferentiated chondrosarcoma (DDCS) is a type of
cartilaginous tumor that is comprised of two distinct
components: (1) low-grade chondrogenic components and
(2) high-grade noncartilaginous sarcoma. It constitutes
1-2% of all primary bone tumors [1]. Approximately 7–20%
of low-grade chondrosarcomas can be expected to de-
differentiate [1–5]. DDCS is slightly more frequent in
males. Patients with DDCS are older than those with
conventional lesions, with a mean age of around 60 years
(range: 15–90 years) [1, 3, 6–9]. ,e most common sites
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were the femur and pelvis, followed by humerus and
scapula [1, 3, 6].
It has been postulated that the dedifferentiated and
cartilaginous components arise from a common primitive
mesenchymal progenitor cell with the ability to express
features of more than one line of mesenchymal differenti-
ation [10]. However, the separation of the two clones is
considered a relatively early event in the tumorigenesis of
DDCS and further alterations may lead to the “switch” to a
high-grade dedifferentiated chondrosarcoma [11–14]. His-
tological features of the anaplastic, noncartilaginous com-
ponent are usually undifferentiated pleomorphic sarcoma
(UPS); however, other types of sarcomas include osteosar-
comas, fibrosarcomas, angiosarcomas, rhabdomyosarcomas,
or leiomyosarcomas [1, 15]. UPS dedifferentiation was re-
ported to be related with poorer outcomes [3]; however,
other studies did not reveal any difference in the clinical
outcome with different types of the dedifferentiated com-
ponent [6, 16].
,e prognosis of DDCS is dismal. Distant metastasis,
especially to the lungs, is common both at the initial pre-
sentation and during or relatively soon after initial treatment
[6, 17, 18]. ,e 5-year survival rate can be as low as 7%–24%,
with median survival ranging from 5 to 13 months
[3, 6, 7, 18–20]. Because of the rarity of DDCS and the
insufficient number of large-scale studies, current reports
regarding the potential prognostic factors are still in-
conclusive. One population-based study using the Surveil-
lance, Epidemiology, and End Results (SEER) database
suggested that chest wall location predicted better prognosis,
whereas larger tumor size, presence of metastases at di-
agnosis, and no surgical resection were significant predictors
of mortality [7]. Another study which utilized the network of
member centers of the European Musculo-Skeletal Oncol-
ogy Society (EMSOS) indicated that pathological fracture,
pelvic location, and increasing age predicted poor survival
and inadequate excision margins were related to local re-
currence and mortality [6]. In addition, there is a lack of
convincing evidence on the effectiveness of chemotherapy
[1, 3, 6, 18, 20].
In this study, we aim to characterize the impact of
clinicopathological features and treatment modalities on the
clinical outcomes of patients with DDCS treated at our
institution and to investigate prognostic factors.
2. Materials and Methods
2.1. Patient Selection. Our IRB approved institutional sar-
coma database includes 13,412 patients from the 1960s to
2017. Study data were collected andmanaged using Research
Electronic Data Capture (REDCap) electronic data capture
tools [21]. ,e database retrospectively collects data from
our institution’s clinical records, on patient demographics,
primary and secondary tumor characteristics, treatment,
follow up, and survival data. We queried the database for
patients who were diagnosed with DDCS that was confirmed
by pathology review at our institution by expert sarcoma
pathologists and were treated in our institution between
1993 and 2017.
A total number of 72 patients were identified. Patient
demographics and treatment characteristics are summarized
in Table 1. Tumor sites are shown in Figure 1. ,ere were 45
men and 27 women with a median age of 60.5 years (range:
29–92 years). Two patients had Ollier’s disease, and one had
hereditary multiple exostoses. Seventeen patients had a
known history of enchondroma (n� 5), low-grade chon-
drosarcoma (n� 5), or a bone lesion without further biopsy
(n� 7) for over 1 year, with the longest present for 15 years.
,e size of the tumor at the time of diagnosis was available in
66 patients, which averaged 12.4 cm (median: 10.4 cm, range:
3.0–46.0 cm). Twenty-three patients (31.9%) presented with
distant metastasis at the time of diagnosis, including lungs
(n� 20, 27.8%), bones (pelvic bone, rib, skull, and spine,
n� 5, 6.9%), soft tissue (buttock, chest wall, groin, and thigh,
n� 4, 5.6%), liver (n� 1, 1.4%), and heart (n� 1, 1.4%), and 3
(4.2%) of them also had regional lymph node involvement.
2.2. Treatment Modalities. Of the 49 patients who did not
have identifiable metastases at the initial presentation (M0),
48 received tumor excision (alone in 32, preoperative ra-
diation therapy (RT) in 6, postoperative RT in 6, and both
pre- and postoperative RT in 4) and one had RTalone for the
primary tumor. Chemotherapy was administered pre-
operatively alone in 3 patients, postoperatively alone in 7
patients, both preoperatively and postoperatively in 3 pa-
tients, and prior to RT in 1 patient. Regimens used include
ifosfamide alone (n� 1) and combinations of doxorubicin
and cisplatin (AP) alone (n� 2) or with ifosfamide (n� 1)/
ifosfamide and etoposide (IE, n� 1), methotrexate with AP
(MAP, n� 5), methotrexate with IE (n� 1), IE alone (n� 1),
and doxorubicin and ifosfamide (AI, n� 1) (1 regimen
unknown). One patient who was treated with MAP also
received the regimen of doxorubicin, ifosfamide and
dacarbazine. Of the 6 patients who received neoadjuvant
chemotherapy, one had 80% tumor necrosis after MAP, one
had 70% necrosis following AP, and another two both had
30% necrosis after the treatment of MAP or methotrexate
with IE.
Of the 23 patients who presented with metastasis (M1),
21 underwent surgical excision of the tumor and/or RTto the
primary tumor (15 surgery alone, 2 surgery then post-
operative RT, 1 surgery with pre- and postoperative RT, and
3 RTalone). Chemotherapy was given to 11 patients, among
whom, 2 received preoperative chemotherapy with MAP or
methotrexate alone, 6 had postoperative chemotherapy with
doxorubicin alone (n� 1), AP (n� 1), or MAP alone (n� 1)
or with ifosfamide (n� 1)/IE (n� 1) (1 regimen unknown), 1
had preoperative methotrexate and cisplatin and post-
operative ifosfamide, 1 received AI after RT, and 1 had
palliative chemotherapy alone (regimen unknown). Only
two of these patients had an assessment of chemotherapy
response following neoadjuvant chemotherapy and surgical
excision, and the necrosis was 5% with MAP and 70% after
methotrexate and cisplatin, respectively.
2.3. Statistical Analysis. Statistical significance between
groups was analyzed using the chi-squared test or Fisher’s
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exact test for categorical variables and Student t test or
Mann–Whitney U nonparametric test for continuous var-
iables.,e estimated overall survival (OS, defined as the time
from diagnosis to death from any cause), progression-free
survival (PFS, the time from diagnosis to progression or
death), local relapse-free survival (LRFS, the time from
diagnosis to the first local relapse after treatment or death
from any cause), and metastasis-free survival (MFS, the time
Table 1: ,e clinicopathological characteristics and treatment modalities in patients with dedifferentiated chondrosarcoma.
Total Nonmetastatic Metastatic
Characteristics 72 49 (68.1%) 23 (31.9%)
Age≤60 years 34 (47.2%) 25 (51.0%) 9 (39.1%)>60 years 38 (52.8%) 24 (49.0%) 14 (60.9%)
Gender
Female 27 (37.5%) 18 (36.7%) 9 (39.1%)
Male 45 (62.5%) 31 (63.3%) 14 (60.9%)
Pathological fracture 28 (38.9%) 16 (32.7%) 12 (52.2%)
Site
Extremity 47 (65.3%) 30 (61.2%) 17 (73.9%)
Trunk 25 (34.7%) 19 (38.8%) 6 (26.1%)
Tumor size≤8 cm 20 (27.8%) 14 (28.6%) 6 (26.1%)>8 cm 48 (66.7%) 31 (63.3%) 17 (73.9%)
Discontinuous 4 (5.6%) 4 (8.2%) 0 (0.0%)
Lymph node involvement 3 (4.2%) 0 (0.0%) 3 (13.0%)
Grade
G2 18 (25.0%) 12 (24.5%) 6 (26.1%)
G3 54 (75.0%) 37 (75.5%) 17 (73.9%)
AJCC 7th edition stage
II 45 (62.5%) 45 (91.8%) 0 (0.0%)
III 4 (5.6%) 4 (8.2%) 0 (0.0%)
IV 23 (31.9%) 0 (0.0%) 23 (100.0%)
Extra-osseous extension 69 (95.8%) 46 (93.9%) 23 (100.0%)
Lymphovascular invasion
No 46 (63.9%) 35 (71.4%) 11 (47.8%)
Yes 9 (12.5%) 5 (10.2%) 4 (17.4%)
NA 17 (23.6%) 9 (18.4%) 8 (34.8%)
Dedifferentiated component
Osteosarcoma 26 (36.1%) 20 (40.8%) 6 (26.1%)
UPS 26 (36.1%) 20 (40.8%) 6 (26.1%)
Fibro/myofibroblastic sarcoma 11 (15.3%) 8 (16.3%) 3 (13.0%)
Undifferentiated spindle cell sarcoma 10 (13.9%) 5 (10.2%) 5 (21.7%)
Rhabdomyosarcoma 2 (2.8%) 1 (2.0%) 1 (4.3%)
Angiosarcoma 1 (1.4%) 1 (2.0%) 0 (0.0%)
Size of dedifferentiated component
Microscopic 11 (15.3%) 8 (16.3%) 3 (13.0%)
Macroscopic 61 (84.7%) 41 (83.7%) 20 (87.0%)
Chemotherapy 25 (34.7%) 14 (28.6%) 11 (47.8%)
Local treatment
Surgery 47 (65.3%) 32 (65.3%) 15 (65.2%)
Radiation 4 (5.6%) 1 (2.0%) 3 (13.0%)
Radiation> surgery 6 (8.3%) 6 (12.2%) 0 (0.0%)
Radiation> surgery> radiation 5 (6.9%) 4 (8.2%) 1 (4.3%)
Surgery> radiation 8 (11.1%) 6 (12.2%) 2 (8.7%)
No surgery or radiation 2 (2.8%) 0 (0.0%) 2 (8.7%)
Surgical margin
R0 53 (73.6%) 39 (79.6%) 14 (60.9%)
R1 2 (2.8%) 2 (4.1%) 0 (0.0%)
R2 11 (15.3%) 7 (14.3%) 4 (17.4%)
No surgery 6 (8.3%) 1 (2.0%) 5 (21.7%)
AJCC, American Joint Committee on Cancer, 7th edition; NA, not available; UPS, undifferentiated pleomorphic sarcoma.
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from diagnosis to the first metastatic relapse after treatment
or death from any cause) were derived using the Kaplan–
Meier method and compared by the Mantel-Cox log-rank
test. ,e multivariate Cox proportional hazard model was
used to investigate significant prognostic factors. ,e sta-
tistical analyses were performed using IBM SPSS Statistics
for Windows, version 23.0 (IBM Corp, Armonk, NY).
Kaplan–-Meier survival curves were generated in R (version
3.4.1; http://www.r-project.org), using the “survminer”
package and the “ggsurvplot” function. All reported P values
were two-sided. ,e level of significance was set at P< 0.05.
3. Results
,e median follow-up was 13 months (range: 1–227
months). ,e OS rates for all patients were 54.9% (95%
confidence interval (CI): 43.1%–66.7%) at 1 year, 35.6%
(95% CI: 24.1%–47.2%) at 2 years, and 19.2% (95% CI:
9.0%–29.5%) at 5 years. ,e median OS for all patients was
13.9 months (95% CI: 6.4–21.5 months). ,e median OS for
patients without metastasis at diagnosis versus those who
presented with metastases was 22.6 months (95% CI: 2.0–
43.1 months) vs. 6.6 months (95% CI: 6.1–7.1 months) with
68.8% (95% CI: 55.4%–82.1%) vs. 26.1% (95% CI: 7.8%–
44.4%) being alive at 1 year and 46.6% (95% CI: 31.9%–
61.3%) vs. 13.0% (95% CI: 0%–27.1%) at 2 years following
diagnosis, respectively (P< 0.001, Figure 2(a)). ,e 1-, 2-,
and 5-year PFS rates in all patients were 33.8% (95% CI:
22.6%–45.0%), 27.7% (95% CI: 16.9%–38.4%), and 21.6%
(95% CI: 11.2%–32.1%), respectively.
On univariate analysis, the presence of distant metastasis
at diagnosis (P< 0.001, Figures 2(a) and 2(b)), pathological
fracture (P< 0.001), lymph node involvement (P< 0.001 for
OS, P � 0.040 for PFS), and positive surgical margin or no
surgery (P � 0.015 for OS, P � 0.028 for PFS) were asso-
ciated with poorer OS and PFS, while size of dedifferentiated
component (P � 0.038) also correlated with PFS. ,ere was
no difference in OS or PFS based on age, gender, site, tumor
size, grade, or RT (Table 2). On multivariate analysis,
pathological fracture (hazard ratio (HR): 2.77, 95% CI:
1.53–5.03, P � 0.001), tumor size larger than 8 cm (HR: 3.43,
95% CI: 1.73–6.79, P< 0.001), lymph node involvement
(HR: 5.27, 95% CI: 1.26–22.08, P � 0.023), metastasis at
diagnosis (HR: 5.31, 95% CI: 2.63–10.74, P< 0.001), extra-
osseous extension (HR: 5.24, 95% CI: 1.11–24.70, P � 0.036),
and UPS component (HR: 2.44, 95% CI: 1.31–4.57,
P � 0.005) correlated with worse OS, whereas surgical re-
section (HR: 0.21, 95% CI: 0.08–0.55, P � 0.002) and che-
motherapy (HR: 0.23, 95% CI: 0.12–0.44, P< 0.001) were
associated with improved OS. Pathological fracture (HR:
2.97, 95% CI: 1.66–5.30, P< 0.001), metastasis at diagnosis
(HR: 5.21, 95% CI: 2.73–9.95, P< 0.001), and chemotherapy
(HR: 0.43, 95% CI: 0.24–0.77, P � 0.005) were also found to
be significant prognostic factors for PFS (Table 3).
Among the 25 patients who received chemotherapy, AP
was significantly associated with improved PFS (median:
26.3 vs. 6.4 months, P � 0.007) but not OS. ,ere was no
difference in OS or PFS based on osteosarcoma component,
UPS, or other regimen received, e.g., methotrexate, MAP,
ifosfamide, or IE. Cox multivariate analysis revealed that
chemotherapy with AP (HR: 0.29, 95% CI: 0.10–0.80,
P � 0.018) correlated with decreased risk while metastasis at
diagnosis (HR: 7.12, 95% CI: 1.18–42.89, P � 0.032) showed
increased risk for PFS.
Among the 49 patients without metastasis at diagnosis,
17 (34.7%) developed a local recurrence. ,e 1-, 2-, and 5-
year LRFS rates were 75.3% (95% CI: 62.3%–88.2%), 66.2%
(51.2%–81.3%), and 56.8% (38.8%–74.8%), respectively.
Pathological fracture (P � 0.008), lymphovascular invasion
(P � 0.024), and surgical margin (P � 0.002, Figure 2(c))
were associated with local recurrence by the univariate
analysis. In the Cox model, the HR for R1/R2 resection was
7.51 (95% CI: 2.51–22.46, P< 0.001) compared to R0 re-
section (Table 4). For the 10 patients with either positive
margin (n � 9) or no surgery (n � 1), RT did not result in
any difference in LRFS (median: 11.0 months without RT
(n � 5) vs. 10.2 months with RT (n � 5), P � 0.727). ,irty-
one (63.3%) patients later developed distant metastases,
including the lungs (n � 28, 57.1%), bones (n � 7, 14.3%),
soft tissue (n � 5, 10.2%), mesentery/omentum (n � 2,
4.1%), liver (n � 1, 2.0%), diaphragm (n � 1, 2.0%), adrenal
glands (n � 1, 2.0%), and appendix (n � 1, 2.0%), at a me-
dian time of 18.1 months (range: 6.2–30.0 months). ,e
MFS rates were 51.6% (95% CI: 37.1%–66.1%) at 1 year,
44.5% (95% CI: 29.9%–59.2%) at 2 years, and 35.7% (95%
CI: 20.8%–50.7%) at 5 years. In the univariate analysis,
12 (17%)
16 (22%)
4 (6%)
1 (1%)
1 (1%)
1 (1%)
8 (11%)
3 (4%)
15 (21%)
2 (3%)
1 (1%)
2 (3%)
1 (1%)
5 (7%)
Figure 1: Anatomic sites of dedifferentiated chondrosarcoma.
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pathological fracture (P � 0.017) and size of dediffer-
entiated component (P � 0.017, Figure 2(d)) correlated
with MFS, whereas only macroscopic dedifferentiated
component was found to be a significant factor for MFS
(HR: 7.78, 95% CI: 1.06–57.17, P � 0.044) by the multi-
variate analysis (Table 4).
4. Discussion
,e majority of literature investigating prognostic factors
affecting DDCS survival were reports on small cohorts from
single centers, and only a fewmore recent ones reported data
collected from multiple centers or a large nationwide
P < 0.0001
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Figure 2: Kaplan–Meier curves. (a) Overall survival and (b) progression-free survival in patients with dedifferentiated chondrosarcoma
with and without metastasis at diagnosis. (c) Local relapse-free survival in patients with nonmetastatic dedifferentiated chondrosarcoma
according to surgical margin. (d) Metastasis-free survival in patients with nonmetastatic dedifferentiated chondrosarcoma according to the
size of dedifferentiation.
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Table 2: Prognostic factors for overall survival and progression-free survival in all patients with dedifferentiated chondrosarcoma by
univariate analysis.
Variable
Overall survival (months) Progression-free survival (months)
Median 95% CI P Median 95% CI P
Overall 13.9 6.4–21.5 6.6 3.7–9.4
Age 0.322 0.424≤60 years 14.2 5.8–22.5 8.4 6.5–10.4>60 years 12.3 1.7–22.9 5.4 3.8–7.0
Gender 0.445 0.628
Female 11.8 7.8–15.9 5.9 3.6–8.2
Male 19.0 8.1–29.9 8.0 4.9–11.2
Pathological fracture <0.001 <0.001
No 22.6 0–46.1 9.2 0–21.1
Yes 7.0 4.6–9.4 4.0 2.3–5.8
Site 0.304 0.920
Extremity 11.8 7.8–15.9 6.1 4.3–7.9
Axial 19.0 9.6–28.4 9.0 6.6–11.3
Tumor size 0.168 0.255≤8 cm 21.9 15.4–28.4 8.4 4.5–12.3>8 cm 11.3 8.1–14.4 6.4 4.6–8.2
Discontinuous 8.5 0–41.8 1.4 0–108.6
Lymph node involvement <0.001 0.040
No 14.2 6.6–21.7 7.2 4.5–9.8
Yes 4.7 1.8–7.6 4.0 2.1–5.9
Distant metastasis <0.001 <0.001
No 22.6 2.0–43.1 10.2 0.1–20.2
Yes 6.6 6.1–7.1 4.0 2.6–5.5
Grade 0.323 0.077
G2 27.4 0.2–54.6 17.8 0–76.7
G3 12.3 9.1–15.5 6.4 4.6–8.2
AJCC stage <0.001 <0.001
II 22.6 2.8–42.4 10.2 0–21.4
III 8.5 0–41.8 1.4 0–108.6
IV 6.6 6.1–7.1 4.0 2.6–5.5
Extraosseous extension 0.108 0.073
No 58.9 56.9
Yes 12.8 8.9–16.6 6.4 3.9–8.9
Lymphovascular invasion 0.128 0.220
No 14.2 0.8–27.6 8.4 5.2–11.5
Yes 15.1 0–38.7 5.7 0.8–10.7
NA 10.3 3.3–17.4 5.1 2.0–8.1
Osteosarcoma component 0.801 0.669
No 12.3 6.7–17.9 6.6 2.7–10.4
Yes 19.0 5.2–32.8 6.4 3.6–9.2
UPS component 0.908 0.596
No 14.2 4.3–24.0 6.1 4.6–7.6
Yes 12.8 3.4–22.2 8.8 4.1–13.5
Size of dedifferentiated component 0.172 0.038
Microscopic 27.4 0–70.4 56.9 0–147.8
Macroscopic 12.3 8.5–16.0 6.1 4.8–7.4
Surgical margin 0.015 0.028
R0 19.1 8.5–29.8 8.4 5.5–11.3
R1/R2 12.3 6.1–18.5 6.6 4.2–9.0
No surgery 6.6 1.5–11.7 3.2 1.7–4.8
Surgery 0.056 0.045
No 6.6 1.5–11.7 3.2 1.7–4.8
Yes 15.1 8.1–22.0 8.0 5.5–10.6
Radiation therapy 0.787 0.903
No 13.1 8.7–17.6 7.2 4.6–9.8
Yes 14.2 0.6–27.7 5.9 1.4–10.4
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database (Table 5). Despite significant breakthroughs in
cancer therapeutics over the past few decades, the prognosis
of this aggressive cancer remains dismal, with a 5-year
survival rate ranging between 0% and 29%. Our series had a
similar 5-year OS of 19.2% (95% CI: 9.0%–29.5%).
Consistent with what has been reported in the literature
(Table 5), DDCS was slightly more frequent in males with a
median age of 60.5 years in our cohort. Compared to
conventional chondrosarcoma, the older age in DDCS is
probably due to the slow indolent process of de-
differentiation, which also makes distant metastasis more
likely to be present at diagnosis.
DDCS are associated with a high rate of pathological
fractures [4, 6], which increases the risk of local recurrence
and predicts poor survival in some studies [6, 25]. In our
series, we observed a similar rate of pathological fracture
(38.9%) and a negative impact of pathological fracture on
both overall survival and disease progression. It is assumed
that pathological fracture could lead to local dissemination
of tumor cells through hematoma and the difficulty in
achieving wide surgical margins in tumor resection [25].
Indeed in our series, R0 resection was achieved in only 54%
of all patients with pathologic fractures, compared with 86%
in those without fractures (P � 0.010).
,e impact of the histological types of dedifferentiation
on the prognosis is still debatable [3, 6, 16]. In the current
study, although UPS component did not show significant
difference in OS by the univariate analysis, it correlated with
a higher risk in mortality by the multivariate analysis. It is
possible that certain factors might have more correlation
with the UPS component. For example, some patients with
UPS component might have been treated more aggressively
due to the presumed more aggressive nature, resulting in an
improved outcome of UPS in the univariate analysis. Other
histological components did not show any influence on OS
or PFS.
Table 2: Continued.
Variable
Overall survival (months) Progression-free survival (months)
Median 95% CI P Median 95% CI P
Chemotherapy 0.205 0.451
No 10.4 5.1–15.8 5.5 4.1–6.9
Yes 23.3 5.6–41.1 9.0 6.5–11.4
AJCC, American Joint Committee on Cancer, 7th edition; CI, confidence interval; NA, not available; UPS, undifferentiated pleomorphic sarcoma.
Table 3: Prognostic factors for overall survival and progression-free survival in all patients with dedifferentiated chondrosarcoma by
multivariate analysis.
Variable
Overall survival Progression-free survival
HR 95.0% CI P HR 95.0% CI P
Pathological fracture
No 1.00 1.00
Yes 2.77 1.53–5.03 0.001 2.97 1.66–5.30 <0.001
Tumor size≤8 cm 1.00 0.001 NS>8 cm 3.43 1.73–6.79 <0.001
Discontinuous 3.73 0.96–14.56 0.058
Lymph node involvement
No 1.00 NS
Yes 5.27 1.26–22.08 0.023
Distant metastasis
No 1.00 1.00
Yes 5.31 2.63–10.74 <0.001 5.21 2.73–9.95 <0.001
Extraosseous extension
No 1.00 NS
Yes 5.24 1.11–24.70 0.036
UPS component
No 1.00 NS
Yes 2.44 1.31–4.57 0.005
Surgical resection
No 1.00 NS
Yes 0.21 0.08–0.55 0.002
Chemotherapy
No 1.00 1.00
Yes 0.23 0.12–0.44 <0.001 0.43 0.24–0.77 0.005
CI, confidence interval; HR, hazard ratio; NS, not significant; UPS, undifferentiated pleomorphic sarcoma.
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Table 4: Significant prognostic factors for local relapse-free survival and metastasis-free survival in patients with nonmetastatic dedif-
ferentiated chondrosarcoma by univariate and multivariate analyses.
Variable
Univariate Multivariate
Median (months) 95% CI P HR 95% CI P
Local relapse-free survival 61.7
Pathological fracture 0.008 NS
No Not reached
Yes 11.0 0–25.5
Lymphovascular invasion 0.024 NS
No Not reached
Yes 11.0 0–22.3
NA 61.7 0–142.4
Surgical margin 0.002
R0 Not reached 1.00 0.004
R1/R2 10.2 1.2–19.1 7.51 2.51–22.46 <0.001
No surgery 61.7 1.98 0.25–15.99 0.520
Metastasis-free survival 18.1 6.2–30.0
Pathological fracture 0.017 NS
No 31.6 0–82.3
Yes 6.4 3.1–9.7
Size of dedifferentiated component 0.017 0.044
Microscopic Not reached 1.00
Macroscopic 9.0 6.4–11.6 7.78 1.06–57.17
CI, confidence interval; HR, hazard ratio; NS, not significant.
Table 5: Studies on the survivorship of dedifferentiated chondrosarcoma cohort since 2000.
Authors Year No. Mean age (range) M : F 5-year OS Comments
van Maldegem et al. [22] 2019 34 NA 17 :17 NA 4 centers, unresectable DDCS, positive factor:doxorubicin monotherapy
Nemecek et al. [9] 2018 33 62.2 (22–90) 16 :17 13.6% 1977–2015, single center, negative factor: CRP
Lex et al. [23] 2018 31 55.6 (33–76) 19 :12 NA 1995–2016, pelvic DDCS, positive factor: widesurgical margin
Dhinsa et al. [24] 2018 21 64 (35–80) NA NA
2000–2010, DDCS with osteosarcoma as
predominant component, positive factor:
chemotherapy
Strotman et al. [7] 2017 159 65.2± 14.7 83 : 76 18% 2001–2011, SEER database positive factor: chest walltumor, negative factor: size> 8 cm, metastases, no
surgical resection
Liu et al. [20] 2017 23 50.4 (32–73) 12 :11 17.4%
2008–2015, single center, negative factors: axial bone
location, lung metastasis, inadequate surgical margin,
incorrect diagnosis before surgery, and pathological
fractures
Albergo et al. [25] 2015 17 NA NA 6% 1970–2012, single center, femoral DDCS negativefactor: pathological fracture
Kawaguchi et al. [8] 2014 41 58 (26–86) 27 :14 15%
1986–2010, single center, positive factor: ifosfamide-
based adjuvant chemotherapy combined with
surgical resection
Italiano et al. [26] 2013 42 NA NA NA
1988–2011, 15 centers, advanced DDCS had higher
response to chemotherapy than conventional
chondrosarcoma
Yokota et al. [18] 2012 9 58.6 (37–86) 4 : 5 0% 1996–2010, single center
Staals et al. [27] 2007 18 46 (22–74) 12 : 6 29%
1970–2002, single center, DDCS that arises in
osteochondroma, positive factor: wide surgical
resection with adjuvant chemotherapy
Grimer et al. [6] 2007 337 Median 59 (15–89) 179 :158 24%
1975–2005, 9 centers, negative factors: pathological
fracture, pelvic location, increasing age, inadequate
margins of excision
Staals et al. [3] 2006 123 59.2 (24–83) 66 : 57 24% 1969–2003, single center, negative factors: metastasis,MFH, high percentage of dedifferentiated component
Bruns et al. [1] 2005 13 59.8 (36–72) 7 : 6 8% 1990–2003, single center, surgery recommended
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,e value of neoadjuvant or adjuvant chemotherapy
remains inconclusive, and the majority of retrospective
studies did not reveal any benefit [1, 3, 6, 18, 20]. In the
current study, similar to the UPS component, chemotherapy
showed a significantly decreased risk in mortality and dis-
ease progression by the multivariate analysis but not uni-
variate analysis. Some patients with more aggressive factors
might have been treated more aggressively with chemo-
therapy, which might have masked the effect of chemo-
therapy in univariate analysis. On the other hand, however,
the limited data on the response to neoadjuvant chemo-
therapy in our series only indicated a relative resistance of
DDCS to most classical anti-bone sarcoma drugs. Several
studies have indicated that ifosfamide-based adjuvant che-
motherapy [8] or doxorubicin monotherapy [22] may offer
survival benefit for patients with DDCS. In our series, the
combination of doxorubicin and cisplatin was found sig-
nificantly associated with delayed disease progression.
However, the analyses were limited due to the small size of
the patients who received chemotherapy and the hetero-
geneity in chemotherapy regimen during the past three
decades.
Surgical resection with complete removal of the tumor is
important for LRFS and should be attempted whenever
possible. ,is has also been supported by other studies,
although the poor prognosis may influence the radicality of
the resection, particularly if it associated with significant
morbidity [5, 6, 20]. Consistent with other studies, the
prognosis is largely determined by the rapid progress of
metastases [1, 7, 20]. ,ere are even fewer data on the in-
fluence of RT in the literature. We did not observe any
difference in the prognosis by RT, including LRFS, even in
patients who did not achieve a complete excision of the
tumor.
,e limitations of this study cannot be ignored, con-
sidering the retrospective nature of this study, long time, and
heterogeneity in practice of treatment of our cohort due to
the rarity of DDCS. ,e future of research potentially lies in
prognostic, multicenter studies.
5. Conclusions
,e prognosis of DDCS is poor. Distant metastases are
frequently seen either at initial presentation or as later
treatment failure. Complete surgical resection remains a
significant prognostic factor for local control. Chemother-
apy with doxorubicin and cisplatin seems to have better PFS.
More prognostic, multicenter clinical trials are warranted to
further stratify patients and explore the effectiveness of
chemotherapy with both classical anticancer drugs and novel
targeted therapies in patients with DDCS.
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